Novartis v. Regeneron: EYLEA® PFS Patent Dispute Dismissed With Prejudice After 4+ Years
Three Novartis entities sued Regeneron Pharmaceuticals in the Northern District of New York asserting US9220631B2 in connection with EYLEA® prefilled syringe. After 1,608 days of litigation, the parties stipulated to dismiss all claims with prejudice — each side bearing its own attorneys’ fees — ending any prospect of re-litigation.
A High-Stakes Ophthalmic IP Dispute That Ended Without a Merits Ruling
In June 2020, Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC (collectively, Novartis) filed an infringement action in the Northern District of New York against Regeneron Pharmaceuticals, Inc., asserting U.S. Patent No. 9,220,631 in connection with Regeneron’s EYLEA® prefilled syringe (PFS) product. EYLEA® (aflibercept) is a blockbuster anti-VEGF therapy primarily indicated for neovascular age-related macular degeneration and diabetic macular edema, making the PFS presentation commercially significant.
After 1,608 days — spanning more than four years — the parties jointly filed a stipulation of dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(ii), dismissing all of Novartis’s claims against Regeneron with prejudice. The stipulation specified that each party would bear its own attorneys’ fees, with no fee award in either direction. A dismissal with prejudice is a final adjudication on the merits for res judicata purposes, meaning Novartis cannot re-assert the same claims against Regeneron based on US9220631B2.
The four-plus-year duration before resolution — without a published merits judgment — suggests the parties likely engaged in protracted discovery, claim construction proceedings, and possibly parallel inter partes review proceedings before reaching a negotiated exit. The symmetric fee arrangement and absence of any damages record is consistent with a confidential settlement or commercial resolution reached privately. The public record does not disclose the specific terms of any underlying commercial agreement between the parties.
Filing to Dismissed with Prejudice in 1608 days
1,608 days — approximately 4.4 years, well above the median for NDNY patent matters
Dismissed with prejudice: what the stipulated exit means for both parties
Rule 41(a)(1)(A)(ii) stipulated dismissal with prejudice explained
A Rule 41(a)(1)(A)(ii) dismissal requires the written consent of all parties and, when entered with prejudice, operates as a final judgment on the merits. Unlike a court-ordered dismissal, it carries no judicial finding on infringement, validity, or damages. The ‘with prejudice’ designation is critical: Novartis is permanently barred from re-asserting the same claims under US9220631B2 against Regeneron on the same accused product.
Permanent bar on re-filingNovartis loses its litigation leverage — permanently
By agreeing to dismissal with prejudice, Novartis has relinquished any right to pursue the asserted claims against Regeneron’s EYLEA® PFS under US9220631B2 in federal court. This outcome may reflect a commercial resolution — licensing, cross-licensing, or a co-existence agreement — or simply a strategic decision to exit costly litigation. The symmetric fee arrangement suggests neither party secured a clear litigation advantage before settlement.
Claims permanently releasedRegeneron clears this patent dispute from its EYLEA® PFS product
Regeneron emerges with the litigation fully resolved and no damages award or injunction on record. The dismissal with prejudice means Novartis cannot re-file identical claims, providing Regeneron with certainty on this specific patent’s enforceability against EYLEA® PFS. However, the patent US9220631B2 itself remains in force and could be asserted against other ophthalmic PFS products or different accused activities not covered by this stipulation.
No liability found on recordEYLEA® PFS competitive position reinforced, but sector-wide patent risk remains
The resolution without a validity ruling means US9220631B2 remains unchallenged on the merits in this forum — a relevant consideration for any other ophthalmic PFS developer or biosimilar entrant. Competitors developing aflibercept biosimilars or alternative anti-VEGF PFS products should treat this patent as active and assertable. The four-year litigation cost and eventual mutual exit also signals the high-stakes nature of ophthalmic drug delivery IP disputes in the NDNY.
Patent validity intactFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novartis Pharma, AG | Company | Global pharmaceutical group — holder of US9220631B2 covering ophthalmic PFS delivery technologySearch in Eureka ↗ |
| Co-Plaintiff | Novartis Pharmaceuticals Corporation | Company | Search in Eureka ↗ |
| Co-Plaintiff | Novartis Technology, LLC | Company | Search in Eureka ↗ |
| Defendant | RegeneronPharmaceuticals, Inc. | Company | Regeneron Pharmaceuticals, Inc. — U.S. biopharmaceutical company and marketer of EYLEA® PFSSearch in Eureka ↗ |
| Plaintiff counsel | Calvin E. Wingfield | Attorney | Counsel for Novartis Pharma, AGSearch in Eureka ↗ |
| Plaintiff counsel | Daniel P. Margolis | Attorney | Counsel for Novartis Pharma, AGSearch in Eureka ↗ |
| Plaintiff counsel | Elizabeth J. Holland | Attorney | Counsel for Novartis Pharma, AGSearch in Eureka ↗ |
| Plaintiff counsel | George R. McGuire | Attorney | Counsel for Novartis Pharma, AGSearch in Eureka ↗ |
| Plaintiff counsel | John Bennett | Attorney | Counsel for Novartis Pharma, AGSearch in Eureka ↗ |
| Plaintiff counsel | Louis Orbach | Attorney | Counsel for Novartis Pharma, AGSearch in Eureka ↗ |
| Plaintiff counsel | Molly Grammel | Attorney | Counsel for Novartis Pharma, AGSearch in Eureka ↗ |
| Plaintiff counsel | William G. James , II | Attorney | Counsel for Novartis Pharma, AGSearch in Eureka ↗ |
| Plaintiff law firm | Allen & Overy LLP | Law Firm | Representing Novartis Pharma, AGSearch in Eureka ↗ |
| Plaintiff law firm | Allen Overy Shearman Sterling US LLP | Law Firm | Representing Novartis Pharma, AGSearch in Eureka ↗ |
| Plaintiff law firm | Bond Schoeneck & King PLLC (Syracuse) | Law Firm | Representing Novartis Pharma, AGSearch in Eureka ↗ |
| Plaintiff law firm | Goodwin Procter LLP | Law Firm | Representing Novartis Pharma, AGSearch in Eureka ↗ |
| Defendant counsel | Anish R. Desai | Attorney | Counsel for RegeneronPharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Brian E. Ferguson | Attorney | Counsel for RegeneronPharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Christopher Pepe | Attorney | Counsel for RegeneronPharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Douglas J. Nash | Attorney | Counsel for RegeneronPharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Elizabeth Weiswasser | Attorney | Counsel for RegeneronPharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Eric Shaun Hochstadt | Attorney | Counsel for RegeneronPharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | John D. Cook | Attorney | Counsel for RegeneronPharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Matthew Sieger | Attorney | Counsel for RegeneronPharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Robert T. Vlasis , III | Attorney | Counsel for RegeneronPharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Barclay Damon LLP (Syracuse Office) | Law Firm | Representing RegeneronPharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Weil, Gotshal & Manges LLP | Law Firm | Representing RegeneronPharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Winston Strawn LLP | Law Firm | Representing RegeneronPharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New York Northern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation’s ‘with prejudice’ language — entered under Rule 41(a)(1)(A)(ii) — is the operative term for both parties’ future positions. It forecloses any re-assertion of the same claims by Novartis against Regeneron on EYLEA® PFS under US9220631B2, functioning as a final judgment for res judicata purposes. Critically, no court finding was made on infringement, validity, or damages, so the patent’s enforceability against third parties is entirely unaffected. The mutual fee-bearing provision is consistent with a negotiated resolution rather than a litigation-determined outcome.
US9220631B2 — Ophthalmic Drug Delivery in Prefilled Syringe Format
US9220631B2, filed under application number US13/750352, covers technology in the ophthalmic drug delivery space — specifically relating to prefilled syringe (PFS) presentations of biologic therapies. The PFS format is clinically significant for anti-VEGF agents such as aflibercept (EYLEA®) because it reduces preparation time, minimises contamination risk, and supports standardised dosing in intravitreal injection procedures. The patent’s claims were asserted by three Novartis entities, suggesting broad licensing authority was consolidated for litigation purposes.
The strategic value of a PFS-specific patent in the ophthalmic biologics sector is substantial. As anti-VEGF therapies transition from vial to prefilled syringe presentations — driven by clinical convenience and payer preference — device-layer IP such as US9220631B2 becomes a critical enforcement lever. Competitors in the space, including biosimilar sponsors filing aflibercept products with PFS delivery, face the risk of infringement assertions even where the biologic compound itself is off-patent or separately licensed. Novartis’s willingness to litigate for over four years underscores the commercial stakes.
Should you run an FTO analysis against US9220631B2?
Any organisation developing or commercialising an ophthalmic biologic — particularly anti-VEGF therapies like aflibercept, ranibizumab, or brolucizumab — in a prefilled syringe format should treat US9220631B2 as a priority FTO target. Biosimilar sponsors seeking FDA approval for EYLEA® biosimilars with PFS presentation are especially exposed: the Novartis-Regeneron dismissal provides no safe harbour, and Novartis retains full enforcement rights against new market entrants.
PatSnap Eureka’s FTO Search Agent enables R&D and regulatory teams to map claim scope against product specifications, identify potential design-arounds, and benchmark against the full Novartis ophthalmic PFS portfolio. The agent surfaces related patents, prosecution history, and IPR outcomes automatically — giving your team a defensible FTO position before IND filing or launch planning, not after a demand letter arrives.
Run a freedom-to-operate analysis on US9220631B2 to assess your product’s exposure
Run FTO in Eureka →Similar Patent Disputes: Ophthalmic Biologics & PFS Drug Delivery Cases
Explore related infringement actions involving ophthalmic biologic PFS technology and anti-VEGF patent disputes in U.S. district courts and the Federal Circuit.
What this case signals for the ophthalmic biologics IP landscape
A four-year dispute ending in mutual exit is rarely purely procedural — it typically reflects commercial negotiation under litigation pressure.
Dismissal with prejudice ≠ patent invalidated — FTO exposure persists for third parties
US9220631B2 was never adjudicated on validity or infringement. Any company developing ophthalmic prefilled syringe products — including aflibercept biosimilar sponsors — should treat this patent as fully enforceable. The Novartis-Regeneron resolution creates no estoppel or prosecution history benefit for third parties.
Symmetric fee split signals a negotiated exit, not a capitulation by either side
When both parties bear their own fees in a multi-year dispute of this complexity, the record is consistent with a commercial resolution rather than a clear litigation win. IP professionals monitoring the Novartis-Regeneron competitive relationship should watch for licensing announcements, collaboration agreements, or co-promotion arrangements that may reflect the underlying deal.
Novartis v RegeneronPharmaceuticals — key questions answered
All claims were dismissed with prejudice by joint stipulation under FRCP 41(a)(1)(A)(ii) on November 13, 2024, after 1,608 days of litigation. Each party was required to bear its own attorneys’ fees. No court finding was made on infringement, validity, or damages.
Novartis asserted U.S. Patent No. 9,220,631 (application no. US13/750352) against Regeneron’s EYLEA® prefilled syringe product. The patent covers ophthalmic drug delivery technology in a prefilled syringe format relevant to anti-VEGF biologic therapies.
No. The dismissal creates no estoppel or prior art effect for third parties. US9220631B2 was never adjudicated on validity or infringement, so it remains fully enforceable against other parties. Biosimilar EYLEA® PFS developers should conduct independent FTO clearance on this patent.
A Rule 41(a)(1)(A)(ii) dismissal requires signed consent from all parties. When entered with prejudice, it operates as a final judgment on the merits for res judicata purposes, permanently barring the plaintiff from re-filing the same claims against the same defendant on the same accused product. No judicial merits finding is made.
The case lasted 1,608 days — approximately 4.4 years — from filing on June 19, 2020 to closure on November 13, 2024. This duration is notably long for a case that ended without a merits judgment and suggests extensive discovery, possible claim construction, and likely parallel proceedings before the parties reached a resolution.
PatSnap Eureka searches patents and litigation data to answer instantly.